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Abstract 
Background: HIV-1 protease (PR) is an essential enzyme for viral production. Thus, PR inhibitors (PIs) are the most 
effective class of anti-HIV drugs. However, the main challenge to the successful use of PI drugs in patient treatment is 
the emergence of multidrug resistant PRs (mdrPRs). This study aimed to develop a fission yeast cell-based system for 
rapid testing of new PIs that combat mdrPRs.
Results: Three mdrPRs were isolated from HIV-infected patients that carried seven (M7PR), ten (M10PR) and eleven 
(M11PR) PR gene mutations, respectively. They were cloned and expressed in fission yeast under an inducible promoter 
to allow the measurement of PR-specific proteolysis and drug resistance. The results showed that all three mdrPRs 
maintained their abilities to proteolyze HIV viral substrates (MA↓CA and p6) and to confer drug resistance. Production 
of these proteins in the fission yeast caused cell growth inhibition, oxidative stress and altered mitochondrial mor-
phologies that led to cell death. Five investigational PIs were used to test the utility of the established yeast system 
with an FDA-approved PI drug Darunavir (DRV) as control. All six compounds suppressed the wildtype PR (wtPR) and 
the M7PR-mediated activities. However, none of them were able to suppress the M10PR or the M11PR.
Conclusions: The three clinically isolated mdrPRs maintained their viral proteolytic activities and drug resistance in the 
fission yeast. Furthermore, those viral mdrPR activities were coupled with the induction of growth inhibition and cell 
death, which could be used to test the PI activities. Indeed, the five investigational PIs and DRV suppressed the wtPR in 
fission yeast as they did in mammalian cells. Significantly, two of the high level mdrPRs (M10PR and M11PR) were resistant 
to all of the existing PI drugs including DRV. This observation underscores the importance of continued searching for 
new PIs against mdrPRs.
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Background
HIV-1 Protease (PR) is an aspartic protease that normally 
presents as a homodimer with each subunit consist-
ing of 99 amino acids (12kD) [1]. The active enzymatic 
site lies between two identical subunits and its activity 
can be blocked by the competitive binding of a specific 
PR inhibitor (PI) such as Indinavir (IDV) [2]. The pri-
mary function of HIV-1 PR is to proteolyze viral Gag-Pol 
polyprotein for the production of viral enzymes (reverse 
transcriptase, PR and integrase), structural proteins and 
the maturation of infectious viral particles [3–6]. Thus, 
HIV-1 PR is an essential enzyme for viral reproduction. 
Because of the important role of HIV-1 PR in HIV-1 
infection, it is a major therapeutic target for antiretroviral 
therapies (ARTs). Indeed, HIV-1 PI is currently one of the 
most effective class of anti-HIV drugs. Monotherapy with 
PI alone can reduce HIV-1 viral loads by several logs [7]. 
When a PI drug is used in combination with other classes 
of anti-HIV drugs in treating HIV-infected patients, 
HIV-1 viral loads could be reduced to a level that often 
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cannot be detected by the conventional laboratory meth-
ods [8, 9].
In spite of the tremendous progress we have made in 
ARTs, one of the main challenges to the success of ARTs 
is viral multidrug resistance (MDR) to the anti-HIV 
drug targets such as PR. The viral multidrug resistant 
PRs (mdrPRs) are developed primarily due to the contin-
ued emergence of viral gene mutations upon prolonged 
ARTs [10, 11]. Multidrug resistant HIV has been found 
in a significant portion of the adult populations in Africa 
that ranged from 10.6% to more than 50% [12]. HIV with 
MDR has also been found in pediatric patients globally 
[13]. Thus, constant effort is required to fight MDR.
One of the reasons why HIV-1 PRs are prone to the 
emergence of drug resistance is because all of the FDA-
approved first generation PI drugs (1stPIs) are relatively 
weak inhibitors. They are small peptidomimetic drugs 
that were designed to mimic the natural HIV-1 PR sub-
strates to compete bindings of the active enzymatic site 
[14]. Upon prolonged ART, the PR viral gene mutations 
could alter the configurations of the active enzymatic 
site that render the PIs non-effective in fitting into the 
active site. For example, a single I84V PR mutation could 
result in cross viral drug resistance to Fosamprenavir 
(FOS), Indinavir (IDV), Atazanavir (AZV), and Tipranavir 
(TPV) [15–17]. Consequently, none of the 1stPIs are able 
to combat MDR. The second generation PIs (2ndPIs) are 
non-peptide P2 ligand-based small molecule drugs that 
were designed to combat MDR based on a new “back-
bone-binding” concept [17, 18]. This concept is based on 
the premise that if a P2 ligand-based PI binds to the S2 
(or its symmetric counterpart S2’) subsite of the active 
enzyme with the maximum hydrogen-bonding affinity, it 
will prevent the PR from accessing its natural viral sub-
strates thus inhibiting the HIV-1 PR activity. In addition, 
the tight P2-S2 binding affinity to the PR makes it more 
tolerable to viral PR gene mutations thus increasing the 
genetic barrier to the development of MDR [19, 20]. This 
new theory led to the development of the latest PI drug 
Darunavir (Prezista™, DRV) that was approved by FDA. 
Indeed, DRV inhibited mdrPRs even when most of the 1stPI 
drugs failed. It also had a higher genetic barrier to the 
development of MDR than the other PI drugs [21].
In spite of these encouraging developments, MDR 
continues to occur including resistance to DRV [22–25]. 
For example, a clinical isolate that contains 20 multidrug 
resistant PR (mdrPR) gene mutations was shown to exhibit 
extreme resistance to many of the PI drugs [22–24]. An 
in  vitro selection study also showed that high levels of 
DRV resistance can be artificially selected in the labora-
tory [25]. These disturbing observations suggested that 
we need to continue developing new PIs that combat 
viral MDR.
Fission yeast (Schizosaccharomyces pombe) has been 
used as a model system in our laboratory to study the 
effects of HIV-1 viral protein R (Vpr) on cell prolifera-
tion, cell cycle G2/M regulation, and cell death/apoptosis 
over two decades [26–30]. A fission yeast cell-based high 
throughput screening system (HTS) for HIV-1 Vpr was 
developed [31]. This HTS platform was later adapted by 
the Molecular Libraries Probe Production Centers Net-
work in the Molecular Libraries Program at NIH. Most 
recently, we showed for the first time that the wild type 
HIV-1 PR (wtPR) proteolyzes the HIV-1 viral substrates in 
fission yeast in the same manner as it does in the mam-
malian cells [32, 33]. As a follow-up of this initial finding, 
in this study, our primary goal was to develop a fission 
yeast cell-based system for functional analysis of HIV-1 
mdrPRs. Our second objective was to validate and test 
some of the newer and 2ndPIs in the established fission 
yeast system. Our long-term goal is to use the established 
fission yeast cell-based system for the development of 
high throughput screening system for new PI drug dis-
covery and for testing of new PIs that are able to continue 
combatting viral MDR.
Results
HIV‑1 mdrPRs cleave the same indigenous viral protein 
substrates in fission yeast
Our prior results have shown that the wtPR cleaved the 
indigenous HIV-1 MA↓CA (DSQNY↓PIVQ) and p6 
(DSFNF↓PQIT) viral targets in the fission yeast as it does 
in the HIV-1 infection of mammalian cells, suggesting 
that the protease activity of HIV-1 wtPR in fission yeast 
was similar to that in mammalian cells [32]. The experi-
ment conducted here was aimed to test whether the three 
clinically isolated HIV-1 mdrPRs were also functional 
as PR enzymes in fission yeast. The same set of HIV-1 
PR cleavage viral targets as described before for testing 
of the wtPR was used. Briefly, a “green fluorescent pro-
tein (GFP) re-localization assay” was used to specifically 
measure the proteolytic enzymatic activities of the HIV-1 
PR in fission yeast. In this assay, two HIV-1 PR natural 
viral substrates MA↓CA and p6 were used to generate 
the “GFP-MA-Vpr” or the “GFP-p6-Vpr” gene fusion, 
in which each encodes a GFP for fluorescent detection, 
a MA↓CA (DSQNY↓PIVQ) or a p6 (DSFNF↓PQIT) 
substrate sequence [34], and a HIV-1 Vpr protein that is 
predominantly localized to the nuclear membrane [35]. 
Therefore, by design, without the PR, the production of 
these two fusion proteins in fission yeast will produce a 
“ring-like” structure on the nuclear membrane because 
of the property of Vpr, i.e., the “Vpr pattern” (Fig.  1A). 
Conversely, separation of GFP from Vpr due to the PR 
cleavage at either the MA↓CA (DSQNY↓PIVQ) or the 
p6 (DSFNF↓PQIT) substrate site will lead to the “GFP 
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Fig. 1 HIV-1 mdrPRs specifically cleave the GFP-MA-Vpr and the GFP-p6-Vpr fusion protein constructs that contain indigenous cleavage sites of HIV-1 
p6 or MA viral proteins. A A schematic drawing to show how the proteolytic test was designed to measure the HIV-1 mdrPR-mediated cleavages of 
the GFP-MA-Vpr or the GFP-p6-Vpr fusion protein constructs in fission yeast. GFP, green fluorescent protein, which typically distributes uniformly 
throughout fission yeast cell, here we referred it as the “GFP pattern” [35, 52]. Vpr, HIV-1 viral protein R normally localizes predominantly on the 
nuclear membrane and appears as a “ring-like” structure. Thus we called it the “Vpr pattern” [35, 52]. The polypeptide shown was derived either from 
the HIV-1 MA↓CA (DSQNY↓PIVQ) or the p6 protein (DSFNF↓PQIT). The arrow indicates the PR cleavage site. B The GFP fluorescent images show 
the status of the HIV-1 mdrPRs-mediated cleavages against the GFP-MA-Vpr fusion protein construct (a) or the GFP-p6-Vpr construct (b) without (left 
column) or with the IDV treatment (right column). The cells were examined 20 h after the PR gene induction. Arrows indicate where the PR cleavage 
sites are. Scale bar 10 µm
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pattern,” i.e., with uniform distribution throughout cells 
[35]. Note that our early test results showed that the PR-
mediated cleavages on the MA↓CA (DSQNY↓PIVQ) and 
on the p6 (DSFNF↓PQIT) substrates were target specific, 
and the wtPR by itself did not interfere with the intracel-
lular localization of GFP or GFP-tagged Vpr in the fission 
yeast [32]. Therefore, we were able to measure the spe-
cific enzymatic activities of HIV-1 mdrPR as designed.
Indeed and as expected, both fusion protein constructs 
showed the “Vpr patterns” when no HIV-1 PRs were pro-
duced, suggesting the GFP-MA-Vpr or the GFP-p6-Vpr 
fusion protein was intact (Fig.  1B, upper rows). How-
ever, when either the wtPR or the mdrPR were expressed 
in the fission yeast cells, the GFPs uniformly distributed 
throughout the cells that displayed the “GFP pattern”. The 
observed re-localization of GFP from the “Vpr pattern” 
to the “GFP pattern” suggested the HIV-1 PR-mediated 
cleavages resulted in separation of the Vpr from the GFP 
(Fig.  1B-a). Similar transitions from the “Vpr pattern” 
to the “GFP pattern” were also seen in the GFP-p6-Vpr 
fusion protein construct in both the wtPR- and the mdr-
PRs-producing cells (Fig. 1B-b).
To test whether HIV-1 mdrPRs retained their drug 
resistant status to some of the well-known PIs, an FDA 
approved PI, Indinavir (IDV, Crixivan™) was used to 
examine whether it could block the proteolytic HIV-1 
mdrPR activities toward the GFP-MA-Vpr or the GFP-
p6-Vpr construct (Fig. 1B). When IDV was added to the 
wtPR-producing cells, it prevented the wtPR protein cleav-
age activities [32]. This inhibitory activity was reflected 
by the reversion of the “GFP pattern” back to the “Vpr 
pattern”. In contrast, the same IDV treatments had no 
effects on the proteolytic activities of the M7PR, M10PR 
and M11PR as the cleavages of the fusion protein con-
structs were evident (Fig.  1B). These observations sug-
gested these mdrPRs were still resistant to IDV. Together, 
these data showed that these three clinical mdrPR isolates 
maintained their viral proteolytic activities and drug 
resistance in the fission yeast.
Production of HIV‑1 mdrPRs prevent yeast colony formation, 
cell growth and lead to cell death
In our earlier report, we observed that HIV-1 wtPR gene 
overexpression prevented yeast colony formation and cell 
proliferation leading to cell death [32, 33]. Here we would 
like to test whether HIV-1 mdrPRs would have the same 
effects on the fission yeast as the wtPR. A yeast colony for-
mation assay was first used to test potential effects of the 
HIV-1 mdrPRs on cellular growth on agar plate. Prior to 
the test, the production of HIV-1 mdrPR proteins in each 
respective strain was first verified by the western blot 
analysis. As shown in Fig. 2A-a, a single band of 12 kDa 
protein was detected reacting to the anti-PR monoclonal 
antibody in each one of the pYZ1N-PR carrying fission 
yeast strains when they were under the gene-inducing 
(PR-on) condition without thiamine. In contrast, no PR 
protein band was seen when thiamine was added to sup-
press the PR gene expressions in the same cells (PR-off), 
indicating the specific PR protein production under the 
inducible nmt1 promoter. Also note that the PR protein 
levels were very similar among all four PR-producing 
cells. The yeast colony formation was first measured in 
the PR-suppressive (PR-off) medium (Fig.  2A-b). Nor-
mal size colonies were seen in both of the wtPR and mdrPR 
cells (top). In contrast, when the same amounts of cells 
were plated on the PR-inducing (PR-on) agar plates, little 
or no colonies were observed (bottom).
To test whether the mdrPRs retained their status of drug 
resistance while they conferred the observed inhibitory 
effects on cellular growth and colony formation, IDV 
was added. As expected, when IDV was added to the 
agar plates producing the mdrPR at increasing concen-
trations between 40 and 400  µg/mL, colony formations 
were restored only on the wtPR-producing plate (Fig. 2A-
b, left top). However, it had no reversing effects on any 
of the mdrPR-producing plates under all three different 
IDV concentrations, suggesting that these three mdrPRs 
remained resistant to IDV.
To have a more comprehensive understanding toward 
the effects of HIV-1 mdrPRs on cellular proliferation, the 
fission yeast cellular growth kinetics was measured. Same 
as the wtPR [32, 33], the expression of all three mdrPRs 
individually completely blocked cellular growth (Fig. 2A-
c, closed circles). Conversely, the same cells under the 
PR-suppressing (PR-off) conditions grew normally with 
nearly indistinguishable growth kinetics (Fig. 2A-c, open 
circles). However, when IDV was added to the PR-pro-
ducing medium prior to the gene induction, it completely 
reversed the effect of HIV-1 wtPR on the cellular growth 
but it had no effect on the mdrPRs (Fig. 2A-c, triangles).
We next tested whether, like the wtPR, prolonged HIV-1 
mdrPR expression kills fission yeast cells. A commercial 
yeast live/dead viability assay was used to determine 
the status of intracellular metabolism [32]. As shown in 
Fig.  2B, when no mdrPRs were produced in the fission 
yeast, cells showed an orange-red color suggesting viable 
and actively respiring cells (Fig.  2B, left column). How-
ever, 24 h after the HIV-1 mdrPR genes were induced, the 
fission yeast cells turned to the greenish yellow (Fig. 2B, 
middle column) indicating that those cells were meta-
bolically dead. Same as the inhibitory effect of IDV on 
PR-induced growth arrest, when IDV was added to the 
PR-producing medium prior to the gene induction, it 
completely prevented the wtPR-induced cell death as 
those cells remained orange-red. In contrast, the same 
treatment of IDV to the mdrPR cells had no effects on 
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Fig. 2 Production of HIV-1 mdrPRs prevent yeast colony formation, cell growth and lead to cell death. A The inducible expression of the wtPR and 
mdrPR genes in fission yeast 24 h after gene induction produced similar levels of HIV-1 PR proteins as detected by the western blot analysis (a), 
prevented the yeast colony formation (b) and the cellular growth over time (c). Note that the IDV treatment only prevented the effect of the wtPR 
but not the mdrPRs. The IDV concentration was added in (b) as shown. 100 µg/ml of IDV was added to the mdrPR-expressing cells in (c). All cells were 
grown at 30 °C and the cell growth was measured by OD650 in the time period as indicated by using spectrophotometer. B Both the wtPR and mdrPR-
induced cell death are shown by a yeast live/dead assay [27, 32]. Note that adding IDV before the gene induction only prevented the cell death 
induced by the wtPR (upper row) but not that by the mdrPR. Pictures were taken at 24 h after the gene induction. IDV (−), i.e., no IDV added; IDV (+), 
100 µg/ml of IDV was added prior to the gene inductions
Page 6 of 15Benko et al. Cell Biosci  (2017) 7:5 
the mdrPRs-induced cell death because all of those cells 
turned into the same greenish yellow colors as the dead 
cells (Fig.  2B, right column). These observations sug-
gested that the production of HIV-1 mdrPRs in the fission 
yeast prevented the colony formation and cell prolifera-
tion that led to cell death.
Expression of HIV‑1 mdrPRs induce cellular oxidative stress 
and changes in mitochondrial morphology
To explore the molecular mechanism underlying HIV-1 
mdrPR-induced cell death, possible intracellular stress 
induced by HIV-1 mdrPRs was determined by the pro-
duction of oxidative stress species (ROS) [29]. A ROS-
specific dye, dihydroethidium (DHE), which produces 
red fluorescence in the presence of ROS, was used to 
measure cellular oxidative stress in the mdrPR-expressing 
cells. As shown in Fig. 3a (left two columns), 24 h after 
the mdrPR gene induction, strong red fluorescence was 
detected in both of the wtPR- and the mdrPR-expressing 
cells; whereas no red fluorescence was observed in the 
control cells (Fig. 3a, top row), suggesting that HIV-1 mdr-
PRs indeed induced the ROS production in the fission 
yeast. Consistent with the notion that the PR-induced 
ROS production was due to the PR enzymatic activities, 
the IDV treatment prior to the PR gene inductions pre-
vented the production of ROS in the wtPR but not in the 
mdrPRs (Fig. 3a, right two columns).
Since HIV-1 wtPR also induces alteration of mitochon-
drial morphologies in fission yeast cells [32], we tested 
whether the mdrPRs have any effects on the mitochondrial 
morphology of the fission yeast cells. Morphology of fis-
sion yeast mitochondria was visualized by staining with 
a mitochondria-specific dye, 2-(4-dimethylaminostyryl)-
1-methylpyridinium iodide (DASPMI) [29, 36]. Consist-
ent with previous descriptions of normal fission yeast 
mitochondrial morphologies [32], the mitochondria in 
the control cells appeared as tubular networks extend-
ing along the periphery of the cells (Fig. 3b, top row). In 
contrast, the mitochondria aggregated in both of the wtPR 
and the mdrPR-expressing cells (Fig. 3b, left column), indi-
cating abnormal mitochondrial morphologies. Consist-
ent with the drug resistant status of the testing mdrPRs, 
the IDV treatment reversed the effect of the wtPR but not 
the effects of the mdrPRs (Fig.  3b, right column). There-
fore, similar to the wtPR, the mdrPRs also caused changes 
in mitochondrial morphology in fission yeast cells.
The second generation protease inhibitors darunavir 
and its derivatives suppress the M7PR but not the M10PR or 
M11PR
One of the ultimate goals of this study was to develop a fis-
sion yeast cell-based system that would allow us to test new 
PIs against those HIV-1 proteases that are already resistant 
to the existing protease inhibitory drugs. By developing 
different fission yeast strains that contain PRs with vari-
ous levels of drug resistance, we were hoping to provide a 
platform to test the drug resistance of HIV-1 PR activities 
at low (M7PR) and high (M10PR or M11PR) levels of MDR.
To test this possibility, we tested six 2ndPIs that included 
an FDA-approved drug, DRV and five research grade 
protease inhibiting compounds UIC-94003, GRL-044-
10A, GRL-0249A, GRL-0489A and GRL-0159A (Fig. 4A). 
They are all P2 ligand-based PI compounds. The five 
research grade PIs are structurally related to DRV. The 
design and synthesis of those compounds were part of 
the effort to improve the P2-S2 bindings in order to esca-
late the genetic barrier to the development of MDR [17]. 
The UIC-94003 and GRL-044-10A are in the same struc-
tural class as the DRV; the GRL-0249A and GRL-0489A 
are in the group of cyclopentyl-THF (cpt-THF); and the 
GRL-0159A is unique [17]. Some of these inhibitors have 
been tested previously in mammalian cells and showed 
various degrees of inhibitory activities against HIV-1 mdr-
PRs [17, 37, 38].
To test whether these compounds had the same inhibi-
tory effects in fission yeast as they did in mammalian 
cells, both of the wtPR- and mdrPR-producing yeast cells 
were treated with 200  µM of each compound prior to 
gene induction. The effects of these newly synthesized 
PIs on HIV-1 PR-induced growth arrest were meas-
ured against the wtPR and three mdrPRs by using a liquid 
growth assay. The yeast growth was measured by OD650 
at 48 h (Fig. 4B) or over a time period of 16–72 h after the 
drug treatments (Additional file  1: Figure S1). No drug 
treatment and the DRV treatment were used here as the 
negative and positive controls, respectively. Consistent 
with the testing results in mammalian cells, all six com-
pounds restored cellular growth in the wtPR-producing 
cells (Fig.  4B-a). Interestingly, however, different levels 
of suppression were observed among those compounds 
in the M7PR-producing cells (Fig. 4B-b). While DRV par-
tially diminished the M7PR-induced growth arrest, the 
UIC-94003 showed the strongest suppression against the 
M7PR with nearly 80% recovery of the cellular growth and 
the GRL-0489A showed the second strongest suppres-
sion against the M7PR with about 60% recovery of the 
cell growth. However, none of the six compounds had 
any clear suppression activities against the M10PR or the 
M11PR (Fig. 4B-c-d; Table 1). Longitudinal testing of these 
6 compounds against the mdrPR-induced growth arrest 
over time (Additional file  1: Figure S1) revealed essen-
tially the same information as shown in Fig. 4B.
Since the compound UIC-94003 showed the strongest 
suppression against the M7PR-mediated growth arrest, we 
decided to test whether this compound could also block 
the proteolytic activities of the wtPR or the M7PR. We also 



















Fig. 3 HIV-1 mdrPR induce oxidative stress and alteration of mitochondrial morphologies. Both of the wtPR and mdrPRs induced oxidative stress a and 
mitochondrial morphological changes b in fission yeast. Unlike the wtPR, the effects induced by mdrPRs were resistant to IDV. Production of reactive 
oxygen species (ROS) was measured by a ROS indicator dye DHE (a). The induction of ROS was shown by increased and visible staining of DHE. The 
mitochondrial morphologies (b) were visualized by staining of the fission yeast cells with a mitochondria-specific fluorescent probe DASPMI [29, 41]. 
Note that normal mitochondria typically appear like threads or necklaces constituted with multiple small dots concentrated around the edge, or 
as a tubular network extended along the cell peripheries. Changes in the mitochondrial morphologies were shown here as different sizes of mito-
chondrial aggregates that were situated almost randomly throughout mdrPR-expressing cells. 100 µg/ml of IDV was added before gene induction of 
all PR-expressing cells. All cells were imaged 24 h after the gene induction
(See figure on next page.)  
Fig. 4 DRV and its derivatives suppress the M7PR but not the M10PR or M11PR. The chemical structures of protease inhibitors, DRV, UIC-94003, 
GRL-0489A, GRL-0159A , GRL-0249A and GRL-044-10A are shown in (A). All six compounds including DRV are P2 ligands [17]. Effects of the newly 
synthesized protease inhibitors on mdrPR-induced growth arrest were measured against the wtPR and mdrPRs by using a liquid growth assay and 
measured by OD650 at 48 h (B). The final drug concentration of 200 µM was used in each of the experiments. DRV was used here as a positive 
control and no drug treatment was used as a negative control. C Effects of the newly synthesize protease inhibitors on mdrPR-mediated protein 
cleavages were tested by using the GFP-p6-Vpr fusion protein construct as described in Fig. 1A. Only the effects of UIC94003 and GRL-0489A on the 
wtPR and the M7PR were tested here because of the initial results shown in (B). DRV was used here as a positive control and no drug treatment was 
used as a negative control, respectively. The mdrPR enzymatic activities were visualized under fluorescent microscopy 20 h after the gene inductions. 
THF, tetrahydrofuran; Cpt, cyclopentyl
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picked GRL-0249A for the comparison purpose because 
it showed little or no suppression against the M7PR. In 
addition, the DRV treatment was used as a positive con-
trol and no drug treatment was used as a negative con-
trol, respectively. The effect of these two compounds on 
HIV-1 PR-mediated protein cleavages was tested by using 
the GFP-p6-Vpr fusion protein construct as described 
in Fig.  1A. The PR enzymatic activities were visual-
ized by monitoring the cellular distribution of the GFP 
under fluorescent microscopy 20 h after the gene induc-
tion. As shown in Fig. 4C-a, the control wtPR-producing 
cells cleaved the GFP-p6-Vpr fusion protein construct as 
expected and showed the “GFP pattern” (Fig.  4C-a, left 
top). The treatment of the same wtPR-producing cells with 
any one of the three compounds completely blocked the 
wtPR activities resulting in the “Vpr pattern”. In contrast, 
only UIC94003 and DRV were able to block the M7PR-
mediated protein cleavages (Fig.  4C-b, lower); whereas 
the GRL-0249A showed no sign of suppression against 
the M7PR-mediated cleavage (Fig. 4C-b, upper). Therefore, 
these testing results shown here suggested that, consist-
ent with some of the prior mammalian results [17, 37, 38], 
all 6 PIs displayed inhibitory activities against the wtPR. 
However, besides DRV, only the UIC-94003 and the GRL-
0489A showed appreciable suppression activities against 
the M7PR. None of the 6 PIs showed inhibitory activities 
against the M10PR and the M11PR that contained high lev-
els of numbers of PR multidrug resistance.
Altogether, these data suggested that the mdrPR-
expressing fission yeast cells described here are suitable 
to be used as a cell-based system to measure the mdrPR-
specific activities or to test the new PIs against MDR.
Discussion
In this study, we demonstrated that three clinical iso-
lates of the mdrPR (M7PR, M10PR and M11PR), when pro-
duced in the fission yeast, maintained their abilities to 
proteolyze their natural viral substrates, i.e., the MA↓CA 
(DSQNY↓PIVQ) or the p6 (DSFNF↓PQIT) (Fig.  1B). 
While they kept their normal enzymatic functions in fis-
sion yeast, they also retained their drug resistance. The 
drug resistant status of these three mdrPRs was supported 
by the observation showing that the IDV treatment sup-
pressed all of the wtPR-mediated protein cleavages and 
cytotoxic activities; whereas it had no suppressive effects 
on the effects of those mdrPRs (Figs. 1, 2, 3). We further 
showed that the expression of these three mdrPR genes 
in the fission yeast prevented the yeast colony forma-
tion and cellular growth (Fig.  2A) that ultimately led to 
cell death (Fig. 2B). Mechanistic analyses suggested that 
the mdrPR-induced cell death were caused by the induc-
tion of the ROS production due to the oxidative stress 
(Fig.  3a) or by the interruption of mitochondrial mor-
phologies (Fig.  3b). Furthermore, the viral PR enzy-
matic activities appeared to couple with the induction 
of growth inhibition and cell death, as the IDV and DRV 
treatments not only prevented the wtPR or the M7PR-
mediated proteolysis (Figs. 1B, 4C), but they also restored 
cell growth of the fission yeast cells (Figs.  2C, 4B). This 
intrinsic coupling provided an opportunity for us to use 
the PR-induced proteolysis and the cell inhibition as the 
endpoints to measure the PI activities. Indeed, we sub-
sequently showed that the 2ndPIs, DRV or its five deriva-
tives were able to inhibit the M7PR-mediated activities in 
addition to the wtPR (Fig. 4; Additional file 1: Figure S1). 
Those results were in general agreement with the inhibi-
tory profiles of these compounds in mammalian cells [17, 
37, 39]. Note that the three mdrPRs described here are 
naturally occurring PRs that were isolated directly from 
the HIV-infected patients. Thus one significant finding 
we reported here is the fact that two of the mdrPRs (M10PR 
and M11PR) were resistant to all of the existing PI drugs 
including the 2ndPI drug, DRV (Table 1, Fig. 4; Additional 
file  1: Figure S1). DRV was designed and approved by 
Table 1 Mutational and multidrug resistant profiles of proteases isolated from HIV-infected patients
The three mutant HIV-1 PRs were isolated from the plasma samples of HIV-infected patients who were cared at the University of Maryland Medical Center. They carried 
seven (M7), ten (M10) and eleven (M11) PR gene mutations, respectively. The wildtype (WT) PR was derived from pNL4-3. The drug resistant profiles were generated 
in a CAP/CLIA accredited hospital laboratory as part of the clinical reports by using the ViroSeq HIV-1 Genotyping System (Abbott Molecular, Chicago, IL). APV, 
Amprenavir; FOS, Fosamprenavir; IDV, Indinavir; SQV, Saquinavir; LPV, Lopinavir + Ritonavir; RTV, Ritonavir; NFV, Nelfinavir; ATV, Atazanavir; TPV, Tipranavir; Drugs in 
parenthesis indicate possible drug resistance
Mutation status Nonsynonymous gene mutations found 
in the PR gene
Known resistance to PI drugs Level of drug resistance to protease 
inhibitors
WT None None None
M7 V32I, L33I, M36I, I54 V, A71 V, G73S, L90 M IDV, SQV, RTV, NFV, ATV (APV, FOS, LPV, 
TPV)
Low
M10 L10I, I13 V, K20R, L33I, M36I, I54 M, A71T, 
G73S, I84 V, L90 M
APV, FOS, IDV, SQV, RTV, NFV, ATV, TPV 
(LPV)
High
M11 L10F, L33F, M46I, I54L, H69 K, A71 V, G73S, 
V77I, V82T, I84 V, L90 M
APV, FOS, IDV, SQV, RTV, NFV, ATV, TPV 
(LPV)
High
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FDA to battle multidrug resistance. This observation cer-
tainly underscores the importance of continued search-
ing for new PIs that combat mdrPRs [21].
The molecular mechanism of how overexpression of 
HIV-1 mdrPRs cause fission yeast cell death is still not 
well understood at the moment. However, results of this 
report on mdrPRs and our earlier study on the wtPR [32] 
suggested that mdrPR-induced cell death in fission yeast 
was reminiscent of PR-induced apoptosis in mamma-
lian cells [29, 40]. This was evident by the fact that HIV-1 
mdrPRs not only triggered the ROS production but also 
caused mitochondrial changes that were linked to apop-
tosis [29, 41]. Given the fact that the PIs are able to block 
mdrPR-induced cell death, this cell death must require the 
PR enzymatic activity. Therefore, it is highly likely that 
HIV-1 PR-induced cell death in fission yeast is at least in 
part the result of mdrPR enzymatic cleavages of host cel-
lular proteins. Indeed, through a genome-wide search of 
multicopy suppressor of HIV-1 wtPR, we found that over-
production of a fission yeast kinase Hhp2 indeed sup-
pressed wtPR-induced cell death in fission yeast [32].
The HIV-1 PR activities have previously been described 
in both budding yeast and fission yeast [32, 33, 42, 43]. 
However, only the wtPR activities have been shown in fis-
sion yeast [32, 33]. The current study was built upon our 
initial findings on the wtPR and further to examine activi-
ties of the mdrPRs that were isolated from HIV-infected 
patients. Thus, this is the first report to show multid-
rug resistance of HIV-1 PR activities in fission yeast. As 
expected, the mdrPRs showed the same enzymatic activi-
ties as the wtPR, and the overall effects of the mdrPRs on 
fission yeast cellular functions were essentially the same 
as the wtPR. However, all three mdrPRs retained their sta-
tus of drug resistance as they showed in human cells. This 
observation is significant because it now allows us to use 
the established fission yeast mdrPR-producing cells for the 
measurement of drug resistance profile of new PIs.
The effects of HIV PRs shown in the fission yeast 
are somewhat different from that shown in the bud-
ding yeast. In budding yeast, HIV-1 PR induces yeast 
cellular growth arrest that leads to cell lysis. The cell 
lysis beaks the cell wall and causes the alteration of the 
plasma membrane, leading to the release of cell con-
tents into the medium [42]. Although HIV-1 PR also 
prevented cell proliferation and induced cell death in fis-
sion yeast (Fig. 2), no cell lysis was seen [33]. This differ-
ence between the two yeasts could be due to, at least in 
part, the relative thick cell wall of fission yeast. Because 
the fission yeast cells remain intact with the production 
of HIV-1 PR, the potential advantage of using the fis-
sion yeast over the budding yeast is that all of the tests 
are within cells. Therefore, it is relatively easy to main-
tain a constant and effective PI drug concentration. The 
downside of using fission yeast is also because of its 
thick cell wall. Depending upon the molecular struc-
ture of a small molecule, sometimes, much higher PI 
drug concentrations than that normally used in mam-
malian cells have to be used to achieve the same inhibi-
tory effect. The actual effective drug concentration varies 
depending upon the molecular weights and structures 
of the small molecule. However, this should not be a 
functional concern for drug testing, because the effects 
shown by some of the PIs in the fission yeast were in 
general agreement with the results of mammalian cells 
[17, 37, 39]. This was further supported by the fact that 
the IDV effectively inhibited the specific effects of HIV-1 
PRs in a dose-dependent manner (Fig. 2A) [32]. Never-
theless, calibration is needed for the comparison of IC50 
that is generated from fission yeast with that of mamma-
lian cells. Note that the IC50 can also be calculated in 
the fission yeast system either based on the % of cellular 
growth and/or the % of proteolytic cleavages of the sub-
strates induced by HIV-1 PRs [32]. However, there was 
no need to calculate IC50 here because none of those 
new PI compounds inhibited the M10PR or the M11PR.
By using the same fission yeast system, we have previ-
ously developed a similar drug testing system for HIV-1 
Vpr [31]. That platform was later selected by the NIH’s 
Molecular Libraries Program. More than 400,000 com-
pounds were successfully screened using the established 
fission yeast cell-based system. A number of lead com-
pounds were identified as the results. They are currently 
under evaluation.
There are a number of potential advantages of using fis-
sion yeast as a cell-based system to study MDR of HIV-1 
PRs. Fission yeast is a simple and unicellular organism 
with cellular functions that in many ways resemble mam-
malian cells [44, 45]. For example, fission yeast has been 
used broadly as a model system to study mammalian cell 
biology. Knowledge gained from this model organism 
has contributed significantly to the field of cancer biol-
ogy [46–48]. Fission yeast cells grow much faster than 
mammalian cells and are easy to maintain in the labora-
tory. Because of the simplicity and amenability of the fis-
sion yeast, the described mdrPR activities in fission yeast 
could open up the possibilities for us to test new protease 
inhibiting drugs against those HIV-1 proteases that are 
already resistant to many of the existing protease inhibi-
tory drugs. Another major advantage of a cell-based 
assay is that it is able to eliminate those compounds that 
confer cytotoxicity to yeast cells. Here we have chosen 
the three mdrPRs for the study because they were isolated 
directly from HIV-infected patients. They represented 
different levels of naturally occurring MDR to the current 
antiretroviral regimens (Table 1). By using the low (M7PR) 
and high (M10PR or M11PR) levels of mdrPRs as described 
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here, these new platforms may enable us to evaluate the 
strength of new PIs against different levels of MDR.
Indeed, in this study, we validated the established fis-
sion yeast system by the use of the latest FDA-approved 
PI drug DRV. The DRV treatment not only inhibited the 
wtPR activities but also reversed the effects of the M7PR 
(Fig.  4). Similar to the DRV effect, all other 5 research 
grade PIs (UIC-94003, GRL-044-10A, GRL-0249A, 
GRL-0489A and GRL-0159A) were also able to suppress, 
with various degrees, the wtPR- and the M7PR-mediated 
proteolysis and growth inhibition (Fig.  4B; Additional 
file 1: Figure S1). In fact, these testing results in the fis-
sion yeast were in general agreement with some of the 
previous mammalian results [17, 37, 39]. For example, 
similar to the DRV effect, the UIC-94003 also suppressed 
the wtPR-mediated activities in the fission yeast. How-
ever, it showed stronger inhibition of the M7PR than the 
DRV in both fission yeast and mammalian cells (Fig. 4B; 
Additional file  1: Figure S1) [17, 37]. The UIC-94003 
was derived from the P2-ligands with incorporation of 
(R)-(hydroxyethyl)sulfonamide isostere [37]. Interest-
ingly, DRV was actually derived from UIC-94003. It was 
a product of the combination of the bis-THF ligand and 
(R)-(hydroxyethyl)sulfonamide isostere with a P2’ sul-
fonamide functionality [49]. Similarly, a slight better 
suppression effect of the GRL-0489A than DRV was also 
observed against the M7PR both in the fission yeast and 
in the mammalian cells (Fig. 4B; Additional file 1: Figure 
S1) [50]. Different from DRV and UIC-94003, the GRL-
0489A was incorporated with a C3-substituted 3-(R)-
hydroxyl group [17, 37].
Interestingly, none of these 6 new 2ndPIs were able to 
suppress the M10PR- and M11PR-mediated activities in the 
fission yeast (Fig. 4B; Additional file 1: Figure S1). How-
ever, this finding is not totally surprising because viral 
multidrug resistance to the existing PIs including the 
DRV has been previously reported [22–25]. For example, 
a clinical isolate that contains 20 mdrPR gene mutations 
exhibited extreme resistance to many of the PI drugs 
[22–24]. An in  vitro selection study also showed that 
high levels of DRV resistance can be artificially selected 
in the laboratory [25]. What is new here, however, is the 
fact that the described high level of MDR is not an artifi-
cially selected effect but rather an actual clinical situation 
where those mdrPRs were isolated directly from HIV-
infected patients.
In summary, we have described activities of three 
clinically isolated mdrPRs in fission yeast. These mdrPRs 
exhibited the same enzymatic activities as the wtPR in 
the fission yeast and in mammalian cells. Moreover, they 
retained their abilities to confer drug resistance. With 
the demonstration of their functional relevance and drug 
resistance in fission yeast, conceivably, we could use 
these established fission yeast strains for the develop-
ment of HTS drug screening systems for future discovery 
of new PIs. The fact that the described mdrPRs were iso-
lated directly from HIV-infected patients and none of the 
six 2ndPIs including DRV were able to suppress the M10PR 
or M11PR, highlights the importance of continued search-
ing for new PIs against MDR. Therefore, our scientific 
contributions described in this report are two folds: (1) 
we described, for the first time, a fission yeast cell-based 
system for HIV-1 mdrPRs, and (2) the mdrPR we used in 
our system were novel targets. They were resistant to all 
of the existing PI drugs including the 2ndPI drugs such as 
DRV and they were isolated directly from HIV-infected 
patients.
Methods
Fission yeast strains, plasmid vectors and gene expression
All of the fission yeast stains used in this study are sum-
marized in Table  2. A commonly used wild type fission 
yeast strain SP223 (h-, ade6-216, leu1-32, ura4-294) was 
used to generate all of its derivatives in this study [51]. 
Standard complete yeast extract with supplement (YES) 
medium, Edinburgh Minimal Medium (EMM), Pombe 
Glutamate Medium (PMG) supplemented with ade-
nine, uracil, leucine, thiamine (20  µM), or G418, when 
necessary, were used for yeast cell growth and plasmid 
selections.
Fission yeast expression plasmid vectors pYZ1N and 
pYZ3N have been previously described [52] and were 
used in this study for gene expression and proteolytic 
studies. Both of these two plasmids carry a thiamine 
repressible no message in thiamine (nmt1) promoter 
where HIV-1 mdrPR genes were only expressed upon gene 
induction. Gene expression can be specifically induced 
or repressed in the absence or presence of 20  µM thia-
mine [53, 54]. The plasmids pYZ1N and pYZ3N (for GFP-
fusion) carry a LEU2 gene as a selection marker. All yeast 
plasmid transformation was done by electroporation 
using a BTX electro cell manipulator (ECM) 600 Sys-
tem protocol 0226 [55]. Anti-HIV PR mouse monoclonal 
antibody was purchased from Abcore Co. (Ramona, CA; 
Cat NO. 11-302-C100).
Isolation of multidrug resistant HIV‑1 proteases (mdrPR) 
and protease inhibitors (PIs)
All of the multi-drug resistant HIV-1 protease genes were 
isolated from normally discarded clinical plasma samples 
of HIV-1 infected patients who were cared at the Uni-
versity of Maryland Medical Center. This study was thus 
considered as waived study by the Institutional Review 
Board because all of the patient’s protected health infor-
mation has been removed. Genotypic and predicted drug 
resistant profiles of the isolated HIV-1 mutant proteases 
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are summarized in Table 1. The wild type HIV-1 protease 
gene was isolated from the commonly used HIV-1 plas-
mid pNL4-3 and used as a control in this study.
An FDA-approved 1stPI drug, Indinavir (IDV, Crixi-
van™), was used primarily to demonstrate drug resist-
ance of the isolated mdrPRs. Another FDA-approved 2ndPI 
drug, Darunavir (DRV, Prezista™) was used as a positive 
control because it has been shown to inhibit a wide spec-
trum of the drug-resistant proteases [49, 56]. Some of the 
experimental PIs (UIC-94003, GRL-0489A, GRL-0249A, 
GRL-0159A, and GRL-044-10A) have been tested in 
mammalian cells (Fig. 4A) [17, 37, 39]. All PI compounds 
were dissolved in 5% DMSO and stored in −20  °C with 
the stock concentration of 10  mM. Unless indicated, 
200 µM of the PIs were used in each experiment.
Synthesis of second generation protease inhibitors
Synthesis and evaluation of the experimental PIs, UIC-
94003, GRL-0489A, GRL-0249A and GRL-044-10A have 
been previously described [17, 37, 39]. Experimental 
details of the syntheses of PIs GRL-0489A, GRL-0249A 
and GRl-044-10A have been described [17, 37, 39, 57]. 
Synthesis of PI UIC-94003 carried out using procedure 
described previously [58]. Synthesis and characterization 
of PI, GRL-0159A was carried out by following procedure 
described previously [59]. The details of the synthesis as 
well as spectral data for compound UIC-94003 and GRL-
0159A are available in the Additional file 2.
Fission yeast assays
To measure cellular growth and gene induction in fis-
sion yeast cells, standard culture techniques were used 
as previously described [26, 60]. Briefly, all fission yeast 
cells were grown either in minimal EMM or PMG media. 
Cells carrying plasmids with the nmt1 promoter were 
maintained selectively in appropriately supplemented 
media with 20  μM thiamine to silence the gene expres-
sion. For the gene induction, cells were first grown to 
mid-log growth phase in the presence of 20 μM thiamine. 
Cells were then washed three times with distilled water 
and diluted to a concentration of approximately 2 × 105 
cells/ml in 5  ml of appropriately supplemented EMM/
PMG media with (gene-off) or without (gene-on) thia-
mine. All of the cells were routinely grown at 30 °C with 
constant shaking of 250–300 rpm. Cell growth was meas-
ured at each time point either by manual counting of the 
cell numbers or by automated measurement of the opti-
cal density (OD650) using a spectrophotometer.
A fission yeast colony-forming ability assay was used to 
investigate the effect of mdrPR gene expression on fission 
Table 2 Fission yeast strains and plasmids
Strains and plasmids Genotype and characters Source or reference
S. pombe strains
 SP223 wild type, h−, ade6-216, leu1-32, ura4-294 Laboratory collection
Plasmids
 pYZ1N Fission yeast expression vector with an inducible nmt1 promoter and a LEU2 selectable marker [50]
 pYZ2N Same as pYZ1N but with a ura4 selectable marker [50]
 pYZ3N Same as pYZ1N but with a 5′ GFP-tag [50]
 pYZ1N-PR Wild type HIV-1 PR gene cloned in pYZ1N
Used to test its effect on cell growth and killing
[32]
 pYZ1N-M7 Drug resistant M7 HIV-1 drPR gene cloned in pYZ1N
Used to test its effect on cell growth and killing
This study
pYZ1N-M10 Drug resistant M10 HIV-1 drPR gene cloned in pYZ1N
Used to test its effect on cell growth and killing
This study
 pYZ1N-M11 Drug resistant M11 HIV-1 drPR gene cloned in pYZ1N
Used to test its effect on cell growth and killing
This study
 pYZ2N-PR Wild type HIV-1 PR gene cloned in pYZ2N
Used to test HIV-1 PR proteolytic cleavage
[32]
 pYZ2N-M7 Drug resistant M7 HIV-1 drPR gene cloned in pYZ2N
Used to test HIV-1 PR proteolytic cleavage
This study
 pYZ2N-M10 Drug resistant M10 HIV-1 drPR gene cloned in pYZ2N
Used to test HIV-1 PR proteolytic cleavage
This study
 pYZ2N-M11 Drug resistant M11 HIV-1 drPR gene cloned in pYZ2N
Used to test HIV-1 PR proteolytic cleavage
This study
 pYZ3N-GFP-MA-Vpr GFP is connected to Vpr in pYZ3N by a polylinker containing the PR cleavage MA↓CA site 
(DSQNY↓PIVQ)
[32]
 pYZ3N-p6-MA-Vpr GFP is connected to Vpr in pYZ3N by a polylinker containing the PR cleavage p6 site (DSFNF↓PQIT) [32]
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yeast cell proliferation and viability [27, 35]. Briefly, fis-
sion yeast cells were prepared the same way as described 
above for yeast cell growth. An aliquot of the mdrPR-on 
or mdrPR-off liquid culture was collected at the indi-
cated time points after mdrPR gene induction and was 
plated onto thiamine-containing (mdrPR-off) agar plates. 
The effect of mdrPR on colony-forming ability was evalu-
ated 6  days after plating by comparing the colony sizes 
between the agar plates with or without the mdrPR pro-
duction. The percentage of cells that formed colonies at 
each time point was calculated from the number of colo-
nies that grew from the mdrPR-on cells as a percentage of 
the number of cells originally plated, which was further 
calibrated by plating efficiency of the mdrPR-off cells.
HIV-1 mdrPR-induced cell death was measured in fis-
sion yeast by using a commercial live/dead yeast viability 
kit (Cat. No. L-7009; Invitrogen, Carlsbad, CA) [27, 32]. 
Briefly, thiamine was removed from a logarithmic phase 
cell culture as described above. Cells were then diluted 
to a concentration of 4 × 104 cells/ml, and re-suspended 
in PMG minimal medium supplemented with or with-
out thiamine to suppress or induce HIV-1 mdrPR gene. 
Cell cultures were grown at 30  °C with constant shak-
ing of 300 rpm, collected at 24 h and resuspended in the 
GH solution (2% d-(+)-glucose +10 mM Na-HEPES, pH 
7.2). A 50 µl aliquot of the FUN-1 solution (80 µM) was 
added to an equal volume of cell suspension. The suspen-
sion was further incubated at 30 °C for 45 min. About 3 µl 
of the suspension was applied onto a glass slide, covered 
with a coverslip and sealed with wax. Status of the cell 
viability was examined by using a Leica DM fluorescent 
microscopy with 11001v2 long path Chroma filter cube. 
Typically, actively respiring cells are marked clearly with 
orange-red fluorescent structures at the maximum wave-
length of approximately 590  nm; whereas metabolically 
inert or dead cells exhibit bright, diffuse, green-yellow 
fluorescence at the maximum wavelength of approxi-
mately 540  nm [27, 32]. FUN1 stained cell images were 
collected at the excitation wavelength of 470  ±  20  nm 
with red, green and blue filter set to generate color 
images by fluorescence merging.
The induction of cellular oxidative stress by mdrPR was 
determined by the production of ROS, which can be 
detected by an ROS-specific dye, dihydroethidium (DHE, 
Sigma) that produces red fluorescence in the presence 
of ROS as described previously [29, 33, 61]. Cells were 
grown as described above. Twenty-four hours after mdrPR 
expression, DHE was added at a concentration of 5 μg/ml 
and the ROS were detected by fluorescence microscopy.
The mitochondrial morphology of fission yeast was 
visualized using a vital dye 2-(4-dimethylaminostyryl)- 
1-methylpyridinium iodide (DASPMI, Sigma) [29, 41]. 
The wtPR and the mdrPR gene expressions were induced 
for 24–36 h as described above. Prior to the observation, 
DASPMI was added to the cells at a concentration of 
75 μg/ml. Cells were incubated at 36 °C for 5 min, recov-
ered by centrifugation in a microcentrifuge for 30  s at 
500 g, resuspended in 20 μl of YES, and then examined 
immediately with the fluorescence microscope (L5 filter) 
at an excitation wavelength of around 470 nm, emission 
wavelength of 560–570 nm.
Fluorescence microscopy
A Leica fluorescence microscope DMR4500B equipped 
with a high performance CCD camera (Hamamatsu) 
and Open-Lab software (Improvision, Inc., Lexington, 
MA) was used for all of the imaging analyses. Fission 
yeast cells were collected onto a regular glass slide and 
covered with a cover slip. For the observation of green 
fluorescence, we used a Leica L5 filter with excitation 
wavelength of 480/40 and emission wavelength of 527/30. 
For red fluorescence, we used a Leica N2.1 filter with 
excitation wavelength of 537.5/22.5 and emission wave-
length of LP590. To observe green-yellow fluorescence, 
we used a Leica YFP filter with excitation wavelength of 
500/20 and emission wavelength of 535/30.
Measurements of HIV‑1 mdrPR activities and substrate 
specificities in fission yeast
To test whether mdrPRs could recognize and cleave the 
same viral protein recognition sites in fission yeast as the 
wtPR, we developed a “GFP re-localization assay” that 
allows us to specifically measure proteolytic activities of 
mdrPRs. Briefly, two of the “GFP-MA-Vpr” and the “GFP-
p6-Vpr” gene fusion constructs were generated in the fis-
sion yeast expression vector pYZ3N [52]. In each of the 
constructs, GFP and Vpr proteins are connected by a pol-
ypeptide linker that contains either a consensus HIV-1 
MA↓CA (DSQNY↓PIVQ) or a p6 (DSFNF↓PQIT) PR 
cleavage sequence [34]. GFP is used for fluorescent detec-
tion and it typically disperses throughout fission yeast 
cells [35, 52]. HIV-1 Vpr is predominantly localized on 
the nuclear membrane in fission yeast [35, 52] (also see 
Fig. 1A). Consequently, fusion protein production, with-
out the protease cleavage, appears predominantly as a 
“ring-like” structure on the nuclear membrane because of 
Vpr, i.e., the “Vpr pattern” [35, 52]. In contrast, separation 
of GFP from Vpr due to the mdrPR cleavage at the sub-
strate site leads to the “GFP pattern” with uniform distri-
bution throughout cells [35, 52]. To examine the mdrPR 
enzymatic activities, fission yeast cells were prepared as 
described above and collected 20 h after gene induction.
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Additional file 1: Figure S1. DRV and its derivatives suppress the M7PR 
but not the M10PR or M11PR over time. The chemical structures of protease 
inhibitors, DRV, UIC-94003, GRL-0489A, GRL-0249A, GRL-0159A and 
GRL-044-10A are shown in (Fig. 4A). All six compounds including DRV are 
P2 ligands [17]. Effects of the newly synthesized protease inhibitors on 
mdrPR-induced growth arrest were measured against the wtPR and mdrPRs 
by using a liquid growth assay and measured by OD650 over a time period 
from 16 to 72 h after the drug treatments and gene inductions. The final 
drug concentration of 200 µM was used in each of the experiments. DRV 
was used here as a positive control and no drug treatment was used as a 
negative control.
Additional file 2. Analytical data for protease inhibitors GRL-0159A and 
UIC-94003.
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